In @_cellandgene, Sanjay Srivastava and Jason C. Foster discuss the changing landscape of CGT, including:

🌐 Market access
🔄 Manufacturing & commercial challenges
👥 The importance of early adoption

Read the article: cellandgene.com/doc/the-new-ec…

Lifileucel, a tumor-infiltrating lymphocyte therapy (TIL), has been approved for advanced #melanoma treatment, making it...

🥇The first FDA-approved TIL therapy
🥇The first FDA-approved immune cell therapy for solid tumours

Read more: nature.com/articles/d4158…

We've got a busy agenda at this year's ISCT 2024! ⬇️

Excitingly, we'll be unveiling our manufacturing platform to the public for the very first time...

Schedule your demo today: oribiotech.com/connect/

'The next steps in CGT involves strategizing how to manage the supply chain effectively.'

According to Adam Siebert, Managing Director at L.E.K. Consulting, a shift is needed to expand #PatientAccess to these life-changing treatments.

Revisit the podcast: open.spotify.com/episode/0AFp4H…

This week, we're attending Alliance for Regenerative Medicine (ARM)’s Cell & Gene: Meeting on the Med!

If you're attending, catch Jason speaking on the roundtable: Innovative approaches: decentralized manufacturing of ATMPs

Full agenda ➡️ meetingonthemed.com/agenda/

For Sickle Cell Disease (SCD) sufferers, CGT offers a new therapeutic avenue.

This #NationalMinorityHealthMonth , we'd like to celebrate therapeutic milestones but, as ever, questions of #patientaccess must be asked.

Read more➡️ statnews.com/2023/12/06/sic…

🧬@Alliancerm's Elisabetta Zanon discusses the commercial and regulatory challenges in the EU with RegMedNet.

She believes industry-wide change is needed to ensure that CGTs are not only approvable but accessible and affordable too.

Read more ➡️regmednet.com/disrupting-cel…

How can CGT commercialization keep pace with scientific advancements?

The development of innovative payment models, regulatory frameworks, and scalable #manufacturing processes requires a collaborative effort from across the industry.

Read more➡️forbes.com/sites/joshuaco…

This year's 6th European CAR-T Cell Meeting showed encouraging #research results across many disease areas, and highlighted the importance of keeping #PatientAccess and safety front of mind.

Read the conference summary ➡️ebmt.org/ebmt/news/repo…

The EBMT European Hematology Association

On Wed 29th, join us at ISCT 2024, where we’ll be unveiling our #manufacturing platform for the very first time.

Our partner CTMC will also be sharing data & insights from their direct experience using the platform.

Schedule a #demo ➡️ oribiotech.com/connect/

🇺🇸 Last week, we had the pleasure of being on-site with CTMC, who we've had the opportunity to work closely with through our LightSpeed Early Access Program.

We also put our heads together to finalize plans for our joint session at ISCT. Stay tuned for more info...👀

Tom Fraser saw his glioblastoma shrink nearly 20% the day after CAR-T treatment at Mass General Brigham and has had no tumor progression for 6 months.

🌟 'It gives me hope for a cure!' - Tom Fraser.

Thank you CNN for sharing Tom's story⬇️ edition.cnn.com/2024/03/13/hea…

#PatientAccess

6 CGTs are on the market.

Commercial challenges mean that the no. of patients who have received CGT is much lower than the no. of eligible patients.

Manufacturing technologies must keep pace with scientific developments to enable #PatientAccess ⬇️

oribiotech.com/patient-access…

With the U.S. FDA's finalized guidelines on Human Genome Editing published earlier this year, Cell&Gene look at what they mean for the industry...

🧬 One-time genome editing
🧬 Phased potency testing
🧬 Accelerated approval pathway

Read more ➡️ cellandgene.com/doc/fda-s-upda…

Meet the Ori team ⬇️

📆 26-27 Mar Marianna Mavropoulou & Kale Feeter at Reuters Pharma USA
📆 27 Mar Thomas Heathman at Deloitte NextGen Therapies IWG
📆 8 Apr Jason C. Foster at Deloitte NextGen Therapies IWG
📆 9-11 Apr Jason & Marianna at Cell&Gene Meeting on the Med

CAR-T #celltherapy put Juju Castaneda Figueroa's acute lymphoblastic leukemia into remission.

Today, aged six, Juju's energy and joy are a testament to the success of CAR-T therapy.

Thank you City of Hope for sharing⬇️ cityofhope.org/car-t-cell-the…

To develop advanced therapies commercially, the industry needs to think like a #manufacturing company.

Andrew Obenshain, bluebird bio CEO shared why at Alliance for Regenerative Medicine (ARM) industry briefing ⬇️ alliancerm.org/arm-event/soti…

Embracing digital technologies signals a pivotal shift towards more efficient, scalable CGT manufacturing, and paves the way for widespread #patientaccess .

Thank you BioSpace for featuring Jason C. Foster: biospace.com/article/how-ce…

Regulatory innovation isn't optional – it's essential to ensure a future with widespread #patientaccess

According to Matthew Hewitt of Charles River Labs, a shift in #manufacturing , delivery, and regulation of these therapies is required.

📺 Catch up on YT: youtube.com/watch?v=xNxaHe…

Catch up with the Ori team at events this month:

📍Matt Todd at Innovate UK's Medicines Manufacturing Data Institute Workshop
📆 21st

📍Marianna Mavropoulou, & Kale Feeter at Reuters Pharma USA
📆 26-27th

📍Thomas Heathman at Deloitte NextGen Therapies IWG
📆 27th